Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reprogramming of updated neurostimulators in chronically implanted patients with Parkinson's disease: A double-blind randomized controlled trial.

Brain stimulation·2025

Same author

Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T-Cell Therapy.

Movement disorders clinical practice·2025

Same author

Deep Brain Stimulation in Pediatric Populations: A Scoping Review of the Clinical Trial Landscape.

Stereotactic and functional neurosurgery·2025

Same author

Challenges in Describing Tremor and Dystonia.

Neurology·2024

Same author

Closed-loop systems for deep brain stimulation to treat neuropsychiatric disorders.

Expert review of medical devices·2024

Same author

Deep Brain Stimulation of the Nucleus Accumbens for Severe Self-Injurious Behavior in Children: A Phase I Pilot Trial.

Biological psychiatry·2024

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Tetrabenazine.

Alfonso Fasano¹, Anna Rita Bentivoglio

¹Università Cattolica del Sacro Cuore, Istituto di Neurologia, Largo Agostino Gemelli, 8-00168 Roma, Italy. alfonso.fasano@rm.unicatt.it

Expert Opinion on Pharmacotherapy

|November 26, 2009

Summary

Tetrabenazine (TBZ) effectively treats hyperkinetic movement disorders like chorea and Tourette syndrome. Studies show TBZ is safe and beneficial for these conditions, with potential for other movement disorders.

Area of Science:

Neuroscience
Pharmacology

Background:

Tetrabenazine (TBZ) depletes presynaptic dopamine in the central nervous system.
TBZ is recognized for its efficacy in hyperkinetic movement disorders.
It offers a favorable safety profile, avoiding extrapyramidal side effects common with neuroleptics.

Purpose of the Study:

To consolidate current knowledge regarding Tetrabenazine (TBZ) usage.
To evaluate the efficacy and safety of TBZ in treating hyperkinetic movement disorders.

Main Methods:

Conducted comprehensive PubMed literature searches using the term 'tetrabenazine'.
Focused on studies published prior to May 2009.
Included relevant studies cited in the initial search results.

Related Experiment Videos

Last Updated: Jun 18, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Main Results:

Consistent favorable outcomes in both short- and long-term studies.
Demonstrated significant efficacy in reducing chorea, including Huntington's disease-associated chorea.
Effective in managing tics associated with Tourette's syndrome and tardive dyskinesias.

Conclusions:

Tetrabenazine (TBZ) is a safe and effective treatment for hyperkinetic movement disorders.
TBZ shows particular efficacy for chorea, Tourette's syndrome tics, and tardive dyskinesias.
Potential therapeutic applications for myoclonus and dystonia warrant further clinical investigation.